Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients

NCT03525210 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.

NCT NCT03525210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03525210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Phase 3
Overall status
Completed
Start date
April 4, 2018
Completion date
July 15, 2020
Enrollment
271 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, human papilloma virus, organ transplants